Renal cell carcinoma 4

Common Name(s)

Renal cell carcinoma 4

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma 4" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma 4" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Renal cell carcinoma 4" returned 27 free, full-text research articles on human participants. First 3 results:

Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
 

Author(s): Tsunenori Kondo, Toshio Takagi, Hirohito Kobayashi, Junpei Iizuka, Taiji Nozaki, Yasunobu Hashimoto, Eri Ikezawa, Kazuhiko Yoshida, Kenji Omae, Kazunari Tanabe

Journal: Jpn. J. Clin. Oncol.. 2014 Mar;44(3):270-7.

 

Poor tolerability to sunitinib with the standard dosing schedule has become an issue. We retrospectively analyzed the treatment efficacy and the profile of adverse events of 2 weeks of sunitinib treatment followed by 1-week-off (Schedule 2/1) and compared the results with the standard ...

Last Updated: 5 Mar 2014

Go To URL
Ribosomal s6 protein kinase 4: a prognostic factor for renal cell carcinoma.
 

Author(s): L Fan, P Li, Z Yin, G Fu, D J Liao, Y Liu, J Zhu, Y Zhang, L Wang, Q Yan, Y Guo, C Shao, G Huang, Z Wang

Journal: Br. J. Cancer. 2013 Sep;109(5):1137-46.

 

The expression and function of ribosomal s6 protein kinase 4 (RSK4) in renal cell carcinoma (RCC) are unknown.

Last Updated: 4 Sep 2013

Go To URL
Attenuation of krüppel-like factor 4 facilitates carcinogenesis by inducing g1/s phase arrest in clear cell renal cell carcinoma.
 

Author(s): Erlin Song, Xin Ma, Hongzhao Li, Peng Zhang, Dong Ni, Weihao Chen, Yu Gao, Yang Fan, Haigang Pang, Taoping Shi, Qiang Ding, Baojun Wang, Yu Zhang, Xu Zhang

Journal:

 

Krüppel-like factor 4 (KLF4) is a transcription factor with diverse functions in various cancer types; however, the function of KLF4 in clear cell renal cell carcinoma (ccRCC) carcinogenesis remains unknown. In this study, we initially examined KLF4 expression by using a cohort of ...

Last Updated: 17 Jul 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Renal cell carcinoma 4" returned 0 free, full-text review articles on human participants.

 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib
 

Status: Not yet recruiting

Condition Summary: Renal Cell Cancer

 

Last Updated: 28 Apr 2009

Go to URL
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
 

Status: Recruiting

Condition Summary: Non Small-cell Lung Cancer; Renal-cell Cancer; Gastrointestinal Stroma Tumor

 

Last Updated: 31 Aug 2014

Go to URL